Home

CARL GOLDFISCHER

CIK 1110780 · last filed 2025-06-20

CARL GOLDFISCHER is a corporate insider who has filed 80 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing, for GLTO, was dated Jun 20, 2025. Across all open-market trades the lifetime net is −$25.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $52.3M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$52.28M

Companies

7

Total Filings

80

Lifetime Open-Market Net

-$25.74M

Filer Profile

Reported Address
161 WEST 61ST STREET
NEW YORK, NY 10022
Related Filers
BAY CITY CAPITAL LLC — 1 joint filings, latest 2020-03-16
Bay City Capital Fund V Co-Investment Fund, L.P. — 1 joint filings, latest 2020-03-16
Bay City Capital Fund V, L.P. — 1 joint filings, latest 2020-03-16
Bay City Capital Management V LLC — 1 joint filings, latest 2020-03-16
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Damora Therapeutics, Inc. (GLTO) Delisted Director 1,160 $28.69 $33.3K $0 7 2025-06-20
Enliven Therapeutics, Inc. (IMRA) Delisted Director 175,845 $14.59 $2.57M $0 2 2022-06-03
Epizyme, Inc. (EPZM) Delisted Director 3,403,005 $1.47 $5.00M -$25.72M 18 2022-05-19
CymaBay Therapeutics, Inc. (CBAY) Delisted Director 4,294 $32.48 $139.5K -$584.7K 11 2019-02-08
ReShape Weightloss Inc. (ETRM) Delisted Director 0 — — $9.81M 21 2017-05-31
PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted Director 314,227 — — $378.0K 10 2011-06-10
MAPP Director 1,859,987 $28.11 $52.28M -$9.63M 6 2010-05-21

Recent Filings

80 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-06-20 Damora Therapeutics, Inc. (GLTO) Delisted Grant (A) — $0 EDGAR
2024-06-21 Damora Therapeutics, Inc. (GLTO) Delisted Grant (A) — $0 EDGAR
2023-06-15 Damora Therapeutics, Inc. (GLTO) Delisted Grant (A) — $0 EDGAR
2022-08-16 — Disp (D) −3,403,005 $0
2022-06-15 Damora Therapeutics, Inc. (GLTO) Delisted Grant (A) — $0 EDGAR
2022-06-03 Enliven Therapeutics, Inc. (IMRA) Delisted Grant (A) — $0 EDGAR
2022-05-19 Epizyme, Inc. (EPZM) Delisted Grant (A) +8,994 $0 EDGAR
2021-11-19 Damora Therapeutics, Inc. (GLTO) Delisted Grant (A) — $0 EDGAR
2021-06-30 Enliven Therapeutics, Inc. (IMRA) Delisted Grant (A) — $0 EDGAR
2021-06-15 Epizyme, Inc. (EPZM) Delisted Grant (A) +8,060 $0 EDGAR
Showing 1–10 of 80
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.